Floatz logo

Glucagon

Type 2 Diabetes Mellitus

Rutgers, The State University of New Jerseyprotein_peptidePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

134 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 49 →

Same molecule, other indications

Glucagon is also rated in:

obesity disorderActive
BB
Indicative · Phase 4
67 / 100
View asset →
type 1 diabetes mellitusDormant
B
Indicative · Phase 3
60 / 100
View asset →
colon carcinomaDormant
B
Indicative · Phase 4
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →